Morning coffee could be the secret to slowing ageing, new study reveals
A groundbreaking study conducted by researchers at Queen Mary University of London has revealed that caffeine, the main stimulant in coffee, directly interacts with key cellular systems that govern energy, stress response, and DNA repair — all essential components of the ageing process.
Published in the journal Microbial Cell, the study details how caffeine activates AMPK (AMP-activated protein kinase), a critical protein often referred to as the cell's 'fuel gauge.' This protein senses when cells are low on energy and responds by kickstarting repair mechanisms and enhancing cellular resilience.
'When your cells are low on energy, AMPK kicks in to help them cope,' explained Dr. Charalampos (Babis) Rallis, Reader in Genetics, Genomics, and Fundamental Cell Biology at Queen Mary's Centre for Molecular Cell Biology. 'Our results show that caffeine helps flip that switch.'
AMPK is not a new discovery in the world of longevity science. It is also the target of metformin, a widely-used diabetes medication that is being investigated for its potential to extend human lifespan, along with another drug called rapamycin.
What sets this study apart is its use of a yeast model to simulate human cellular behaviour. The team demonstrated that caffeine's activation of AMPK improves cell growth, enhances DNA repair capabilities, and strengthens stress responses. These mechanisms are directly tied to the processes of ageing and the development of age-related diseases.
Dr. John-Patrick Alao, a postdoctoral scientist and lead author of the study, emphasized the significance of the findings: 'These results help explain why caffeine might be beneficial for health and longevity. And they open up exciting possibilities for future research into how we might trigger these effects more directly — with diet, lifestyle, or new medicines.'
While more research is needed to translate these findings into practical treatments or recommendations, the study reinforces previous observational data suggesting that moderate coffee consumption is associated with lower risks of diseases like Alzheimer's, Parkinson's, and certain cancers.
With over two billion cups of coffee consumed globally every day, the implications of caffeine's influence on cellular ageing are massive. Researchers hope that this study paves the way for developing new therapeutic strategies aimed at mimicking caffeine's effects for those who may not consume it regularly or cannot tolerate it.
For now, coffee lovers have even more reason to savour their daily brew — it might just be the world'smost delicious anti-ageing elixir.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
What is Leqembi? The first Alzheimer's treatment approved today in Saudi Arabia
Leqembi targets beta-amyloid plaques in the brain, aiming to slow Alzheimer's progression in patients with mild cognitive impairment The Saudi Food and Drug Authority (SFDA) announced today the official approval of Leqembi, the first Alzheimer's treatment available in Saudi Arabia. This approval marks a significant milestone in addressing Alzheimer's, a progressive brain disorder that affects memory and thinking skills. Leqembi is specifically indicated for patients experiencing mild cognitive impairment or mild dementia caused by Alzheimer's, who have either no copies or just one copy of a particular gene variant known as apolipoprotein E4 (ApoE4). How Leqembi Works: Targeting the Root Cause Leqembi represents an innovative approach to treating Alzheimer's. Unlike many existing therapies that only ease symptoms, this drug aims to slow the actual progression of the disease. It is a biologic therapy developed using monoclonal antibody technology, a sophisticated method that creates lab-produced molecules designed to target specific proteins in the body. In this case, Leqembi works by targeting beta-amyloid proteins, which tend to build up in the brains of Alzheimer's patients and form sticky clumps called plaques. These plaques are widely believed to contribute to the cognitive decline seen in the disease. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Patrocinio: Unsold Furniture Liquidation 2024 (Prices May Surprise You) Unsold Furniture | Search Ads Learn More Undo Specifically, brain plaques, known as amyloid plaques, are abnormal clumps of protein fragments called beta-amyloid that build up in the brain, especially in people with Alzheimer's. These plaques interfere with the normal communication between nerve cells (neurons), disrupting brain function. By helping reduce the formation of these harmful plaques, Leqembi seeks to protect brain function and slow cognitive decline over time. The treatment is given through an intravenous infusion every two weeks, allowing the drug to circulate and act within the brain. Proven Effectiveness Backed by Clinical Studies Before approving Leqembi, the SFDA thoroughly reviewed evidence of its safety, effectiveness, quality, and compliance with regulatory standards. Clinical trials revealed that Leqembi significantly slows the progression of Alzheimer's disease compared to a placebo. The effectiveness was measured using established clinical scales that assess memory, thinking, and daily functioning abilities. However, like all medications, Leqembi can cause side effects. The most commonly reported include: Headaches Reactions related to the infusion process Amyloid-related imaging abnormalities (ARIA), a term that refers to unusual changes detected in brain MRI scans. These abnormalities may include swelling (cerebral edema) or tiny brain bleeds (microhemorrhages). Because ARIA can only be detected through brain scans, careful monitoring is essential throughout treatment. Safety First: The Need for Careful Patient Monitoring The SFDA stresses the importance of ongoing patient monitoring during treatment. Before starting Leqembi, patients must be tested for their ApoE4 gene status, as this influences the risk of side effects. Those with two copies of the ApoE4 gene are not currently eligible for the treatment due to a higher likelihood of complications. Additionally, the pharmaceutical company responsible for Leqembi is required to track how the drug performs once it is in use (post-marketing surveillance). They must regularly submit updated reports on safety and effectiveness to the SFDA. A comprehensive risk management plan is also mandatory to ensure the treatment is used safely and responsibly. Advancing Healthcare with Biotechnology in Saudi Arabia The approval of Leqembi reflects the SFDA's commitment to expanding access to advanced and high-quality medical treatments, especially those developed through cutting-edge biotechnological methods. Biotech therapies like Leqembi represent a rapidly growing field in medicine, offering new hope for diseases that previously had limited treatment options. About the SFDA Established in 2003 under the Council of Ministers' resolution, the Saudi Food and Drug Authority is an independent regulatory body directly reporting to the President of the Council of Ministers. Its main mission is to safeguard public health by ensuring the safety and quality of food, medicines, biological and chemical substances, medical devices, and cosmetics. The SFDA oversees all procedures related to these products, aiming to protect both human and animal health throughout the Kingdom.
Time of India
2 hours ago
- Time of India
Could walking be the key to lowering Alzheimer's risk?
If you've been debating whether to get up and stretch your legs today, new research may give you the nudge you need. A fresh study, planned to be presented at the Alzheimer's Association International Conference this week, suggests that simply walking more could slow cognitive decline, especially in people genetically predisposed to Alzheimer's disease. Researchers followed nearly 3,000 adults between the ages of 70 and 79 for a decade and tracked their walking habits and how those habits correlated with brain function over time. Participants who either maintained or increased their walking levels showed notable improvements in executive function and processing speed, according to the study, which is currently available as a preprint and hasn't yet undergone peer review. The findings appeared especially promising among individuals with the APOE4 genotype, a known genetic risk factor for Alzheimer's. According to Dr. Cindy Barha, senior study author and assistant professor of kinesiology at the University of Calgary, the results highlight the danger of inactivity as we age. The genetic link Alzheimer's disease, the most common form of dementia, is believed to result from a buildup of toxic plaques in the brain that interfere with how nerve cells communicate. Over time, those neurons die, leading to memory loss, confusion, behavioral changes, and eventually, physical deterioration. There is no cure. The genetic story behind Alzheimer's is complex, but APOE genes play a central role. One particular variant, APOE4, is linked to a reduced ability to clear those brain plaques. According to the U.S. National Institutes of Health, between 15% and 25% of people carry this gene, though it can only be identified through genetic testing. What's compelling is that those at higher risk may benefit the most. 'Before the study started, we thought APOE4 carriers had more room to grow in terms of cognition, since they may already have been experiencing some cognitive decline,' Barha explained. 'They also have more room to show improvement.' She also speculated that participants who knew they carried APOE4 may have been more motivated to change their behavior during the study. Either way, the cognitive benefits were clear. But how does movement in the body affect what's happening in the brain? Experts believe exercise may increase the production of brain-derived neurotrophic factor (BDNF), a protein often compared to fertilizer for brain cells. 'We're thinking there are proteins released from the muscle that travel to the brain and, either across the blood-brain barrier or at the blood-brain barrier, start a reaction that eventually leads to increases in BDNF within the brain,' Barha explained.
Hindustan Times
9 hours ago
- Hindustan Times
Walking daily may protect your brain from Alzheimer's, reveals 10-year study
If you've been looking for a reason to lace up your shoes and hit the pavement, a recent long-term study may be the motivation you need. Walking daily has been linked to a reduced risk of cognitive decline, especially for those with a genetic predisposition to Alzheimer's disease. The effects of walking extend beyond mere physical exercise; they also have a positive impact on brain health(Unsplash) The findings are based on a comprehensive study published in the journal JAMA and presented at the Alzheimer's Association International Conference, which tracked nearly 3,000 participants aged 70 to 79 over the years. Researchers noted their daily walking habits and found that maintaining or increasing these habits led to improved processing speed and executive function, key aspects of cognitive health. Dr Cindy Barha, the study's lead author and an assistant professor at the University of Calgary, emphasised the importance of combating sedentary behaviour. She suggests incorporating short walking sessions throughout the day to break up long periods of sitting. What is Alzheimer's disease? Alzheimer's disease is a complex disorder that represents a severe form of dementia. It is characterised by the accumulation of harmful plaques in the brain, which disrupt communication between nerve cells and eventually lead to their death. As nerve cells deteriorate, individuals may encounter: Memory loss: Difficulty recalling recent events or personal experiences. Difficulty recalling recent events or personal experiences. Confusion: Disorientation, especially in familiar environments. Disorientation, especially in familiar environments. Personality changes: Noticeable shifts in behaviour or mood. Unfortunately, there is currently no cure for Alzheimer's, making prevention strategies increasingly important. What is the role of genetics in Alzheimer's disease? Genetic factors play a significant role in one's likelihood of developing Alzheimer's. "Notably, a gene variant known as APOE4 can make it more challenging for the brain to remove the plaques associated with the disease. Approximately 15% to 25% of the population carries this variant, which can only be identified through genetic testing," neurologist Dr Neha Kapoor tells Health Shots. How does Alzheimer's affect the mind and body? While the study didn't prescribe a specific walking routine, Dr Barha proposed that breaking up periods of inactivity with multiple short walks throughout the day can greatly benefit cognitive health. Walking recommendations Frequency: Aim for multiple short walking sessions throughout the day. Aim for multiple short walking sessions throughout the day. Consistency: Maintain a steady walking habit from year to year. Maintain a steady walking habit from year to year. Goal: A previous study published in JAMA Neurology suggested that walking approximately 3,800 steps per day can reduce the risk of dementia by 25%. Also read: Walking 7,000 steps is good enough, says new study What happens to the brain during Alzheimer's? The effects of walking extend beyond mere physical exercise. They also have a positive impact on brain health. Here are a couple of theories explaining how regular physical activity may promote cognitive function: Increased BDNF production: Exercise boosts the production of brain-derived neurotrophic factor (BDNF), a protein crucial for neuronal growth and connectivity. Dr Barha explains that muscular activity seems to release proteins that travel to the brain, enhancing BDNF levels. Exercise boosts the production of brain-derived neurotrophic factor (BDNF), a protein crucial for neuronal growth and connectivity. Dr Barha explains that muscular activity seems to release proteins that travel to the brain, enhancing BDNF levels. Reduction in neuroinflammation: 'Physical activity may also mitigate neuroinflammation, a common issue in Alzheimer's patients. The brain dispatches immune cells called microglia to clear away plaque, but chronic inflammation can lead them to attack healthy cells as well. Regular exercise can improve the functioning of these microglia,' shares Dr Kapoor. Every step truly counts. Dr Christiane Wrann, another expert associated with the study, highlighted that it's never too late to begin an exercise routine. Whether you're a seasoned walker or a newcomer, the key takeaway is to find an activity you enjoy and stick to it. Tips for getting started:
